来氟米特治疗以肾病综合征为主要表现的IgA肾病的对照研究  

Control study of leflunomide in the treatment of IgA nephropathy （nephrotic syndrome type）

作　　者：何燕[1] 王海水[2] 顾海东[1] 汉吉洪[1] 胡昭[3] 

机构地区：[1]山东省日照市人民医院肾内科,276826 [2]山东省日照市中医医院普外科 [3]山东大学齐鲁医院肾内科

出　　处：《临床肾脏病杂志》2009年第7期307-309,共3页Journal Of Clinical Nephrology

摘　　要：目的探讨来氟米特治疗以肾病综合征为主要表现的IgA肾病患者的疗效及安全性。方法60例患者随机分为治疗组和对照组，每组30例。治疗组应用泼尼松联合来氟米特治疗；对照组应用泼尼松联合环磷酰胺冲击治疗。观察治疗前后24h尿蛋白定量，血浆白蛋白，肝、肾功能及治疗后药物的不良反应。结果治疗组与对照组的总有效率分别为86．7％和83．3％；不良反应总发生率分别为30．0％和73．3％。结论来氟米特联合泼尼松治疗以肾病综合征为主要表现的IgA肾病疗效可靠，不良反应发生少，为临床治疗提供的一种新的方法。Objective To discuss the efficacy and safety of leflunomide in the treatment of IgA nephropathy （nephrotic syndrome type）. Methods Sixty cases were randomly divided into treatment group and control group. In the treatment group （n = 30）, the patients were treated with leflunomide in combination with prednisone therapy. In the control group （n = 30）, the patients were treated with prednisone combined with cyclophosphamide pulse therapy; Urine protein, renal function, blood albumin before and after treatment, and adverse reactions were observed. Results Total effective rate in treatment and control groups was 86. 7% and 83.3% respectively. The overall incidence of adverse reactions in treatment and control groups was 30% and 73. 3% respectively. Conclusion The curative effectiveness of leflunomide plus prednisone in the treatment of IgA nephropathy （nephrotic syndrome type） was reliable

关 键 词：肾病综合征 肾病 IGA 病理学 

分 类 号：R586[医药卫生—内分泌] R692[医药卫生—内科学]